Suppr超能文献

急性和慢性疾病状态下药物水平的解读

Interpretation of drug levels in acute and chronic disease states.

作者信息

Perucca E, Grimaldi R, Crema A

出版信息

Clin Pharmacokinet. 1985 Nov-Dec;10(6):498-513. doi: 10.2165/00003088-198510060-00003.

Abstract

Serum drug concentration monitoring can be an invaluable aid to patient management, particularly in certain pathological conditions when individualisation of dosage is particularly critical. To be clinically useful, however, drug levels must be interpreted in the context of all factors that could influence the correlation between the concentration of the drug in plasma and the intensity of action. Several such factors may be operating in acute and chronic disease states. For example, a number of pathological conditions are associated with marked changes in the fraction of free, pharmacologically active drug in plasma and this will result in disruption of the normal relationship between total serum drug level and effect, as seen for phenytoin in uraemia. An altered response to a given serum drug level in disease states may also be caused by changes in tissue distribution, by abnormal accumulation of pharmacologically active metabolites in plasma or by changes in end-organ responsiveness. The latter are best illustrated by the altered sensitivity to digoxin in patients with various conditions, including hypokalaemia and thyroid disease. In addition to the factors listed above, consideration should also be given to potential interactions with concomitantly used drugs and to the possibility of analytical errors, especially in view of the evidence that the performance of otherwise reliable drug assays may be grossly impaired in certain diseases (e.g. uraemia), due to abnormal plasma composition and/or accumulation of interfering metabolites. In view of these complexities, a correct interpretation of serum drug levels requires a good knowledge of clinical pharmacology and a close collaboration between physician and laboratory. In any case, serum drug concentrations, like other laboratory tests, are not a substitute for careful patient observation, and any decision about drug treatment should be primarily based upon evaluation of the clinical state and, whenever possible, direct measurement of drug effects.

摘要

血清药物浓度监测对患者管理可能是一项非常宝贵的辅助手段,尤其是在某些病理状况下,此时剂量个体化尤为关键。然而,要在临床上发挥作用,必须在所有可能影响血浆中药物浓度与作用强度之间相关性的因素背景下解读药物水平。在急性和慢性疾病状态下,可能有多种此类因素在起作用。例如,一些病理状况与血浆中游离的、具有药理活性的药物比例的显著变化有关,这将导致血清总药物水平与效应之间的正常关系被破坏,如在尿毒症患者中苯妥英钠的情况。疾病状态下对给定血清药物水平的反应改变也可能由组织分布变化、血浆中药理活性代谢物的异常蓄积或终末器官反应性变化引起。后者在患有各种疾病(包括低钾血症和甲状腺疾病)的患者对洋地黄毒苷敏感性改变中得到了最好的体现。除上述因素外,还应考虑与同时使用的药物的潜在相互作用以及分析误差的可能性,特别是鉴于有证据表明,在某些疾病(如尿毒症)中,由于血浆成分异常和/或干扰性代谢物的蓄积,原本可靠的药物检测性能可能会严重受损。鉴于这些复杂性,正确解读血清药物水平需要具备良好的临床药理学知识以及医生与实验室之间的密切合作。无论如何,血清药物浓度与其他实验室检查一样,不能替代对患者的仔细观察,任何关于药物治疗的决定都应主要基于对临床状态的评估,并尽可能直接测量药物效应。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验